Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss

The relation between inflammatory markers, adiposity and disease is under extensive study. Here we tested the hypothesis that the immunomodulatory protein pentraxin 3 (PTX3) is associated with adiposity in the general population.

[1]  G. Sinagra,et al.  Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome , 2013, Cardiovascular Diabetology.

[2]  R. Ajisaka,et al.  Association of plasma pentraxin 3 with arterial stiffness in overweight and obese individuals. , 2013, American journal of hypertension.

[3]  J. Carrero,et al.  Elevated Circulating Levels and Tissue Expression of Pentraxin 3 in Uremia: A Reflection of Endothelial Dysfunction , 2013, PloS one.

[4]  W. Ryu,et al.  Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. , 2012, Atherosclerosis.

[5]  M. Shlipak,et al.  Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. , 2012, American heart journal.

[6]  P. Cieślik,et al.  Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications , 2012, Autoimmunity.

[7]  J. Moreno-Navarrete,et al.  Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. , 2011, American journal of physiology. Endocrinology and metabolism.

[8]  J. Carrero,et al.  Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[9]  G. Johansson,et al.  Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET) , 2011, Journal of internal medicine.

[10]  T. Kodama,et al.  Reciprocal Contribution of Pentraxin 3 and C‐Reactive Protein to Obesity and Metabolic Syndrome , 2010, Obesity.

[11]  H. Sasai,et al.  Is pentraxin 3 involved in obesity-induced decrease in arterial distensibility? , 2010, Journal of atherosclerosis and thrombosis.

[12]  H. Staines,et al.  The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain , 2009, Thrombosis and Haemostasis.

[13]  G. Biolo,et al.  Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile , 2009, Clinical and Experimental Medicine.

[14]  A. Mantovani,et al.  Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. , 2009, Atherosclerosis.

[15]  T. Kodama,et al.  Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations , 2009, Clinical chemistry and laboratory medicine.

[16]  C. Garlanda,et al.  Pentraxins, humoral innate immunity and tissue injury. , 2008, Current opinion in immunology.

[17]  Martina Heer,et al.  Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3. , 2008, The Journal of clinical endocrinology and metabolism.

[18]  J. Carrero,et al.  Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[19]  Philippe Pibarot,et al.  Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J. Carrero,et al.  The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. , 2008, QJM : monthly journal of the Association of Physicians.

[21]  C. Garlanda,et al.  Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction , 2008, Circulation.

[22]  J. Murabito,et al.  Visceral and Subcutaneous Adipose Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative Stress: The Framingham Heart Study , 2007, Circulation.

[23]  J. Carrero,et al.  Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[24]  Udo Hoffmann,et al.  Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study , 2007, Circulation.

[25]  L. Lönn,et al.  Practical approach for estimation of subcutaneous and visceral adipose tissue , 2007, Clinical physiology and functional imaging.

[26]  L. Hansson,et al.  Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m2 from the cystatin C values in mg/L , 2007, Scandinavian journal of clinical and laboratory investigation.

[27]  Lars Lind,et al.  A Comparison of Three Different Methods to Evaluate Endothelium-Dependent Vasodilation in the Elderly: The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[28]  A. Larsson,et al.  Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. , 2005, Atherosclerosis.

[29]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[30]  C. Garlanda,et al.  Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. , 2005, Annual review of immunology.

[31]  L. Hansson,et al.  Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L , 2004, Scandinavian journal of clinical and laboratory investigation.

[32]  O. Bezy,et al.  Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. , 2003, Journal of lipid research.

[33]  A. Mantovani,et al.  Biochemical and functional characterization of the interaction between pentraxin 3 and C1q , 2003, European journal of immunology.

[34]  S. Kritchevsky,et al.  Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. , 2003, Diabetes care.

[35]  P. Scherer,et al.  ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism , 2002, Trends in Endocrinology & Metabolism.

[36]  L. Reis,et al.  TSG‐14 transgenic mice have improved survival to endotoxemia and to CLP‐induced sepsis , 2001, Journal of leukocyte biology.

[37]  P. McKeigue,et al.  Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[38]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[39]  M. Rocchi,et al.  Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. , 1992, The Journal of biological chemistry.